Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxLSE:VRCI Current Ratio is 3.94 as of Dec. 2025, which is 8% below its 10-year median of 4.26. The stock has 3 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Verici Dx ranks better than 78.87% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Verici Dx's current ratio for the quarter that ended in Dec. 2025 was 3.94.
Verici Dx has a current ratio of 3.94. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Verici Dx's Current Ratio or its related term are showing as below:
LSE:VRCI'
s Current Ratio Range Over the Past 10 Years
Min: 1.14 Med: 4.26 Max: 26.52
Current: 3.94
During the past 6 years, Verici Dx's highest Current Ratio was 26.52. The lowest was 1.14. And the median was 4.26.
LSE:VRCI's Current Ratio is ranked better than 78.87% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1
vs LSE:VRCI: 3.94
Verici Dx (LSE:VRCI) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Verici Dx Current Ratio Related Terms
Verici Dx Current Ratio Historical Data
* Premium members only.
The historical data trend for Verici Dx's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:VRCI vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Verici Dx's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Current Ratio distribution charts can be found below:
* The bar in red indicates where Verici Dx's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (LSE:VRCI) has a Current Ratio of 3.94 as of Dec. 2025. This is near median its historical median of 4.26. Over the past decade, Verici Dx's Current Ratio has ranged from 1.14 to 26.52. According to the industry distribution chart, Verici Dx ranks #45 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 21.1%.
Is Verici Dx's Current Ratio too high?
Verici Dx's current Current Ratio of 3.94 is near median its 10-year median of 4.26. Over the past 10 years, this metric has ranged from a low of 1.14 to a high of 26.52. The Medical Diagnostics & Research industry median Current Ratio is 2.10. Verici Dx's value of 3.94 is 87.6% above this industry median. Based on the distribution chart, Verici Dx ranks #45 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Verici Dx's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #45 out of 213 companies for Current Ratio. This places Verici Dx in the top 21% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.10. Verici Dx's value of 3.94 is 87.6% above this benchmark. Historically, Verici Dx's own Current Ratio has ranged from 1.14 to 26.52 over the past decade. While the company's 10-year median is 4.26 vs. the industry median of 2.10, Verici Dx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verici Dx's current Current Ratio of 3.94 is 87.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current Current Ratio is 3.94, which is near median its own 10-year median of 4.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (LSE:VRCI) has a current Current Ratio of 3.94. The current Current Ratio is 3.94, which is near median its 10-year median of 4.26 and 87.6% above the Medical Diagnostics & Research industry median of 2.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Verici Dx (LSE:VRCI), the current Current Ratio is 3.94 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VRCI has been successfully added to your 
